The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism

• Status: Unknown status
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

we propose that bromocriptine may be an alternative treatment of primary aldosteronism, both APA and BAH.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Treatments: Bromocriptine

Criteria

Inclusion Criteria:

• 20-60y/o hyperaldosteronsim patients

Exclusion Criteria:

• Malignancy

• Bed-ridden

• Psychological disease